Chief Financial Officer (CFO)
Mr. Edmund Hen
Chief Financial Officer (CFO) of
Yong Ding Biopharm
Mr. Edmund Hen is an experienced financial executive with over two decades of expertise in corporate finance, capital markets, and business strategy. As Chief Financial Officer (CFO) at Yong Ding Biopharm, he brings extensive knowledge in financial management, regulatory compliance, and business development. His leadership has been instrumental in supporting the company’s growth initiatives and expanding its market presence.
“At Yong Ding Biopharm, we recognize that sound financial stewardship is essential for driving sustainable growth. Through collaboration, innovation, and disciplined financial strategy, we are committed to advancing our mission and delivering long-term value to patients and stakeholders.”
Academic Excellence
Master of Science in Professional Accounting, University College London, UK
Bachelor of Science in Accounting and Finance, University of East Anglia, UK
Professional Achievements
Led the IPO process for several companies, including roadshows, secondary offerings, and bond offerings.
Oversaw the resolution of halted stock trading and legal class actions, maintaining investor confidence.
Managed M&A activities, investor relations, and corporate finance for companies listed on U.S. and international capital markets.
Instrumental in expanding companies’ operations across multiple regions, including China and Southeast Asia.
Professional Experience
CFO, XXXX Holdings Ltd (NASDAQ: XXX) (2008 – 2024)
CFO, Sichuan Guanglin Electric Co., Ltd. (2006 – 2008)
CFO, Guanhong (China) Limited (2005 – 2006)
Accounting Manager, Dickson Concepts Limited (2002 – 2005)
Internal Auditor, PRG Profits Recovery Ltd (2000 – 2002)
Auditor, Arthur Anderson, Hong Kong (1995 – 2000)
Vision and Leadership
Mr. Hen's leadership in finance, coupled with his extensive experience in the capital markets, plays a key role in steering Yong Ding Biopharm toward continued growth and success. His strategic financial oversight ensures that the company remains at the forefront of innovation and global healthcare solutions.
